About the RG012-06 Study

The RG012-06 study is a clinical trial for the investigational drug, RG-012. This is a Phase I study designed to evaluate the safety and tolerability of RG-012.

This clinical trial is recruiting male and female participants with a diagnosis of Alport syndrome.

All participants in this study will receive the investigational drug.

Travel and lodging assistance is available, as well as in-home visits.

You may be qualified for this study if you:

  • Have been diagnosed with Alport syndrome
  • Have not received a kidney transplant
  • Are currently not on dialysis

To locate your nearest study center, please use the site locator. The study team will contact you to review the study requirements and discuss whether you may be eligible to participate.